Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Subcutaneous Immunoglobulin (Hizentra) in Patients With Dermatomyositis: A Proof of Concept Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02271165
Recruitment Status : Terminated (Difficult recruitment)
First Posted : October 22, 2014
Last Update Posted : May 16, 2018
Sponsor:
Information provided by (Responsible Party):
marinos dalakas, Thomas Jefferson University

Brief Summary:
The purpose of the study is to evaluate the effectiveness and safety of human immunoglobulin SCIg in the form of Hizentra (Immune globulin Subcutaneous) in patients with Dermatomyositis. Hizentra provides effective protection against infection by maintaining a steady and normal level of immunoglobulin in the body) in patients with primary immunodeficiency. At present, patients with steroid resistant dermatomyositis can only be treated with IVIg (The healthy antibodies in IVIG can block the damaging antibodies that attack muscle and skin in dermatomyositis) treatment. An evaluation can then be made to see if SCIg is a suitable replacement and exerts immunomodulatory effect on complement antibodies.

Condition or disease Intervention/treatment Phase
Dermatomyositis Drug: Immunoglobulin (Hizentra) Early Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 2 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : November 2014
Actual Primary Completion Date : March 2, 2017
Actual Study Completion Date : March 2, 2017


Arm Intervention/treatment
Active Comparator: IVIg naive
Patients naïve to IVIg who have active disease responding to corticosteroids or are corticosteroid-dependent, will be also included. Before these patients enter the study, they will receive 3 monthly infusions of IVIg starting with the standard dose of 2gram/kg/month and followed with monthly maintenance of 1 or 2gram/kg according to their response.
Drug: Immunoglobulin (Hizentra)
Other Name: Immunoglobulin subcutaneous (human) 20% liquid, Hizentra

Active Comparator: non-IVIg naive
Participants already on IVIg will be observed for 12 weeks under their existing IVIg regimen and will undergo measurements of their muscle strength, skin changes, assessments of their daily activities and quality of life (QoL) every 4 weeks at scheduled visits for monthly maintenance IVIg infusions (weeks 0,4,8,12).
Drug: Immunoglobulin (Hizentra)
Other Name: Immunoglobulin subcutaneous (human) 20% liquid, Hizentra




Primary Outcome Measures :
  1. The primary outcome is a change in strength (based on MRC sumscores) from baseline (enrollment) to the mean change at weeks 16, 20, 24 and 28. [ Time Frame: The primary outcome is a change in strength (based on MRC sumscores) from baseline (enrollment) to the mean change at weeks 16, 20, 24 and 28. ]
    The primary outcome is a change in strength (based on MRC sumscores) from baseline (enrollment) to the mean change at weeks 16, 20, 24 and 28.


Secondary Outcome Measures :
  1. The main secondary outcome is the preference of the participant for SCIg compared with IVIg [ Time Frame: The main secondary outcome is the preference of the participant for SCIg compared with IVIg ]
    Secondary outcome measures will be a) patient preference, based on the number of participants who prefer SCIg to IVIg (a home-made questionnaire will be utilized to capture preference in the most unbiased way; b) average change in Quality of life scores between week 12 and 28; c) effect on the complement consumption in serum; d) Immunological parameters on the repeated skin biopsies; and e) adverse events as reported at each visit. Accordingly, information will be obtained on the superiority of SCIg vs. IVIg



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Men or woman aged >18 years
  2. Diagnosis of DM based on standard criteria
  3. Receiving the equivalent of at least 0.4 g/kg IVIg every 4 weeks (IVIg group only)
  4. Established response to IVIg or dependence on IVIg to maintain status established either by symptomatic worsening of condition at the end of the inter-dose interval for both groups or by worsening after reduction of the dose within the previous 12 months (IVIg group only)
  5. IVIg regimen stable for 12 weeks while on IVIg (minor changes are permitted provided that the dose change is 15% or less) (IVIg group only)
  6. Stable dosing with steroids and/or other immunosuppressives for 12 weeks with no changes schedule or intended.

Exclusion Criteria:

  1. Pregnancy, planned pregnancy, breast feeding or unwillingness to practice contraception
  2. Severe concurrent medical conditions which would prevent treatment or assessment, including significant hematological, renal or liver dysfunction or malignancies
  3. Initiation or immunomodulatory treatment other than IVIg in the past 24 weeks or modification of immunomodulatory treatment other than IVIg in the past 12 weeks.
  4. Participation in trial of an investigational medicinal product in the past 12 weeks
  5. Presence of skin infection unrelated to dermatomyositis, severe skin involvement

Presence of any other medical condition, which in the opinion of the investigator might interfere with performance or interpretation of this study.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02271165


Locations
Layout table for location information
United States, Pennsylvania
Thomas Jefferson University
Philadelphia, Pennsylvania, United States, 19107
Sponsors and Collaborators
Thomas Jefferson University

Layout table for additonal information
Responsible Party: marinos dalakas, Professor of Neurology, Thomas Jefferson University
ClinicalTrials.gov Identifier: NCT02271165     History of Changes
Other Study ID Numbers: 13P.192
First Posted: October 22, 2014    Key Record Dates
Last Update Posted: May 16, 2018
Last Verified: May 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Dermatomyositis
Polymyositis
Myositis
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Connective Tissue Diseases
Skin Diseases
Immunoglobulins
Antibodies
Immunoglobulin G
Immunologic Factors
Physiological Effects of Drugs